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Objective: Network meta-analysis (NMA) may produce more precise e timates of treatment effects than 
pairwise meta-analysis. We examined the relative contribution of network paths of different lengths to 
estimates of treatment effects. 
Study Design and Setting: We analyzed 213 published NMAs. We categorized network shapes 
according to the presence or absence of at least one cl sed loop (non-star or star network), and derived 
graph density, radius and diameter. We identified paths of different lengths and calculated their percentage 
contribution to each NMA effect estimate, based on their contribution matrix. 
Results: Among the 213 NMAs included in analyses, 33% of the information came from paths of length 1 
(direct evidence), 47% from paths of length 2 (indirect paths with one intermediate treatment) and 20%
from paths of length 3. The contribution of paths of different lengths depended on the size of networks, 
presence of closed loops, graph radius, density and diameter. Longer paths contribute more as the number 
of treatments and loops, the graph radius and diameter increase. 
Conclusion: The contribution of different paths depends on the siz and structure of networks, with 
important implications for assessing the risk of bias and confidence in NMA results. 
Keywords: network of interventions; network meta-analysis; paths of evidence; flow networks; study 
contribution; flow decomposition 
Running title: contribution of indirect evidence 







Theoretical considerations and empirical data show that network meta-analysis (NMA) may 
produce more precise relative treatment effects than pairwise meta-analysis (1–4). The theoretical 
advantage of NMA arises from the integration of direct evidence - from studies directly comparing a 
particular treatment comparison - and indirect evidnce from paths with one or more intermediate 
comparators (1,5,6). Methods for deriving the amount that each direct and indirect evidence route 
contributes for a given treatment comparison are requi d to estimate the amount of total indirect evid nce 
in networks of clinical trials. The difficulty of answering this question, and the lack of empirical data, is 
because until recently, methods for deriving the amount that each path of direct and indirect evidence 
contributes were lacking. In a simple triangular network comparing treatments ABC, the AB treatment 
effect can be produced by synthesizing the estimate from the direct AB comparison with the indirect 
estimate via C. The inverse of the variance of the dir ct and the indirect effect, standardized over th  sum 
of the inverse variances, is the relative contribution of the two sources of evidence. However, in more 
extensive networks with more complex structures,, it is not straightforward to identify the relative 
contributions of different sources.  
 The decomposition of estimates of treatment effects from NMA by the contributing sources of 
evidence is of interest for several reasons. Different paths of evidence might be associated with different 
characteristics, e.g. risk of bias, whose influence on the results could be critical (7,8). Moreover, indirect 
effects derived from longer routes require stronger assumptions: the transitivity assumption requires that 
treatment C is similar when it appears in AC and BC trials in terms of dose and dosing or administration 
route. Transitivity is violated if the treatment in question differs systematically between trials (9).
Similarly, if the relative effectiveness of the interventions influences the choice of the comparison 
treatment, then the assumption of transitivity is violated. In other words, the distribution of effect 
modifiers of the relative treatment effects should be similar in AC and BC trials to obtain a valid AB 
indirect comparison (9). 
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In the present study we examined whether the contribution of indirect evidence might justify the 
additional assumptions required for longer paths in more extensive networks. Building on theoretical work 
(10–13), we recently developed a method to compute the contribution of different pieces of evidence to 
NMA relative treatment effects (14). Here we apply this approach to assess the contribution of paths of 
direct and indirect evidence in published NMAs of randomized control trials (RCTs). 
2 Methods 
2.1 Identification of networks and inclusion criteria 
Petropoulou et al. compiled a database of 456 NMAs of RCTs including at least four different 
interventions published up to April 14, 2015; details bout the search strategy, inclusion criteria and data 
extraction can be found elsewhere (15). For ease of use and reproducibility, we created a REDcap 
database containing the 456 NMAs and developed the R package nmadb to make it publicly accessible 
(16). In the present study, we included only NMAs with binary or continuous outcome data that allowed 
replication of the analyses. We excluded networks with evidence of inconsistency, defined by either a P 
value < 0.10 in the design-by-treatment interaction est (17,18) or by more than 15% of comparisons 
having a P value < 0.10 for SIDE (Separate Indirect from Direct Evidence) splitting (19). 
2.2 Characteristics of the networks 
For each network, we recorded the total number of studies, the total number of interventions, the 
direction of the outcome (beneficial or harmful), and the type of the outcome (objective, semi-objectiv  or 
subjective). The type of outcome was defined according to the definitions given by Turner et al. In 
particular, objective outcomes refer to all-cause mortality. Semi-objective outcomes refer to cause-spcific 
mortality, major morbidity event, composite mortality or morbidity, obstetric outcomes, internal strucure, 
external structure, surgical device success or failure, withdrawals or drop-outs, resource use, and a 
hospital stay or process measures. Subjective outcomes refer to pain, mental health outcomes, 
dichotomous biological markers, quality of life or functioning, consumption, satisfaction with care, 
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general physical health, adverse events, infection or new disease, continuation or termination of the 
condition being treated, and composite endpoint (including at most one mortality or morbidity endpoint) 
(20). We derived several characteristics relevant to the network structure. In particular, we categorized the 
shape of the network according to the presence or absence of at least one closed loop (non-star or star 
network), and for each network, we derived the graph density, radius and diameter (21). Graph density 
shows how well connected a network is and is calculted as 

 ( )
 where 	 is the number of comparisons 
with direct data (at least one direct study) and 
 is the number of treatments in the network. The definition 
of the density can be understood as the number of comparisons with direct data over the number of all 
possible comparisons. As the minimum number of direct comparisons is 
 − 1, density is always equal or 
larger than 2/








. For example, a star network with five treatments ha a density of 40%, whereas a star network of 10 
treatments has a density of 20%. The eccentricity of a node is the maximum length of the shortest path
from this node to any other. Graph radius is defined as the minimum eccentricity and graph diameter as 
the maximum eccentricity of a graph. We also recorded the degrees of freedom from the design-by-
treatment interaction model. A review of metrics adapted from graph theory to report on NMA geometry 
can be found in (22). 
2.3 Contribution of different direct and indirect paths in NMA 
Each relative treatment effect in a network is estima ed using direct and indirect evidence through 
various sources. Consider for example the network plot of a published NMA in Figure 1 (23). The 
network consists of 16 studies comparing four interventions for the treatment of achalasia of the 
esophagus: laparoscopic Heller myotomy (LHM), endoscopic balloon dilation (EBD), endoscopic 
botulinum toxin injection (EBTI) and open Heller myotomy (OHM). Clinical success expressed as odds 
ratios (OR) was the study outcome, as defined by clinical scores, manometric findings, or clinical 
interviews at 12 months. The summary OR from NMA comparing EBD and OHM is derived by 
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considering direct evidence from studies of EBD vs OHM and indirect information via LHM or via the 
EBD – EBTI – LHM – OHM paths. Paths can have different lengths; paths of length 1 represent direct 
evidence, paths of length 2 represent indirect evidence with one intermediate comparator, and so on. 
The calculation of the contribution of a path to the estimation of a relative treatment effect is 
complex. We previously suggested a method (14) that utilizes the observation by König et al. (10), that 
each relative treatment effect can be transformed into a flow graph. We briefly describe the method using 
the example of Figure 1. NMA is performed as a two-stage regression model (6); in the first stage, we 
perform classic pairwise meta-analyses for all comparisons with direct evidence to obtain the summary 
estimates from the head to head trials. As the network plot of Figure 1 shows, direct evidence exists for all 
except the OHM vs EBTI comparison. In the second stage, we combine the five summary treatment 
effects from the direct comparisons to derive summary treatment effects for all combinations of 
treatments. The projection matrix that maps the dirct effects on NMA effects involves the variances of 
the direct summary effects and depends on the network’s structure. As heterogeneity is included in , the 
assumption of common or different heterogeneity values across comparisons impacts on the calculations 
of the projection matrix. Each row of the matrix refers to a single NMA summary treatment effect and 
columns refer to direct evidence. Elements of each row give information on the contribution of each 
treatment comparison with direct data to the particular NMA effect and can thus be seen as a 
generalization of pairwise meta-analysis weights.  
Our method decomposes each row of the matrix to contributions of direct and indirect paths (14). 
Supplementary Material Table 1 shows the projection matrix of the network of interventions for the 
treatment of achalasia. We focus on the comparison EBD vs OHM; Figure 1 shows the row of the 
projection matrix corresponding to the NMA relative OR between drugs EBD and OHM. The particular 
row shows how much each direct comparison contributes to the estimation of the EBD vs OHM NMA 
effect and in particular, it shows that the information “flows” from EBD to OHM via three paths of 
evidence. This flow of evidence is illustrated in Fgure 1, which shows the contribution of the direct and 
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the two different paths of indirect evidence in theestimation of the EBD versus OHM NMA relative 
treatment effect. Direct evidence contributes 55% to the estimation, the EBD – LHM – OHM path follows 
with 30% and the EBD – EBTI – LHM – OHM contributes 15%. Note that the comparison LHM vs OHM 
is involved in two paths (EBD – LHM – OHM and EBD – EBTI – LHM - OHM) and thus contributes 
more than the other comparisons that provide indirect evidence to the EBD vs OHM comparison. 
Each row of Supplementary Material Table 1 can be transformed into a flow graph such as the 
graph of Figure 1 by using a general algorithm. We us  the flow graphs to identify the paths that 
contribute information in each NMA treatment effect, and we derive their contribution. Described in detail 
in (14), the generalized algorithm can handle networks f any size. 
In this empirical study, we address the contribution of different paths. However, it is also possible 
to split the contribution of paths to contributions of comparisons and studies. For the achalasia example, 
the contributions of comparisons and individual studies to all NMA treatment effects are given in 
Supplementary Material Tables 2, and 3, respectively and the general algorithm is described in 
Supplementary Material Text 1. 
2.4 Analysis 
We re-analyzed each network using netmeta (24) by including the effect sizes reported in the 
original publication in a random-effects model using a common heterogeneity parameter. We then 
identified the paths of different lengths (e.g. the paths of three different colors shown in Figure 1) and 
calculated their percentage contribution to each NMA effect. The paths’ contributions were then 
aggregated by network and across networks. We plotted box plots for the contributions of paths according 
to their length. We also derived the mean contribution of paths of length between 1 and 5 and cumulative 
contributions of paths up to length 1 to 5, and we presented them separately according to the number of 
treatments in the network, the degrees of freedom, the radius, the graph density and the diameter. We then 
studied the relationship between the cumulative contribution of paths and the number of treatments in a 
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network. For direct paths (of length 1) the relationship is derived analytically as 2/(number of treatments). 
For indirect paths of length 2-5, we fitted restricted cubic splines, weighted according to the logarithm of 
the inverse of the standard errors. We also plotted th  relationship between the cumulative distribution of 
paths and the derived characteristics relevant to the network structure (degrees of freedom from the 
design-by-treatment interaction model, graph density, radius and diameter). 
For the calculations of contribution of paths, we programmed the package nma-contribution 
in the Haskell programming language, which is freely available (25). We provide an R markdown file to 
reproduce all analyses of this paper as Supplementary M terial. There was no protocol or registration f r 
this empirical study.  
3 Results 
3.1 Network characteristics 
Out of the 456 published NMAs included in (15), 213 networks met the inclusion criteria. The full 
selection process for the included NMAs is presented in Supplementary Material Figure 1. About three 
quarters had a binary outcome (n=165, 77%) and one quarter a continuous outcome (n=48, 23%). Among 
NMAs with a binary outcome the odds ratio (OR) was the most popular effect measure (n=104) while the 
mean difference was most commonly used in NMAs with a continuous outcome (n=35). The number of 
treatments varied from 4 to 45 with a median of 6 (interquartile range [IQR] 5-9) and the median of 
included studies per network was 19 (IQR 11-33). A third of networks (68, 32%) did not have any closed 
loops. Most networks addressed either an objective (78, 37%) or a semi-objective (87, 41%) outcome. 
Median graph density, radius and diameter were 0.42, 1 and 2, respectively. Table 1 summarizes the main 
characteristics of the included NMAs. 
(Table 1 here) 
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3.2 Contribution of paths of any length in NMA treatment effects 
Figure 2 shows the path contributions for all networks ordered by their length. The median 
contribution of direct evidence (paths of length 1) was 33%. Around half of the information (46%) came 
from paths of length 2 (indirect paths with one intermediate treatment). The contribution of paths with 
lengths 3 and 4 (indirect paths with 2 and 3 intermediate comparators respectively) was also substantial. 
Among networks of any size, paths of length greater than 6 contributed only minimally (less than 2% 
each) to the estimation of NMA effects. 
The contribution of paths of different lengths depend d on the size of the network. Figure 3 shows 
the cumulative path contribution for paths of length 1 to 5 per number of treatments in the network. We 
excluded the largest network with 45 treatments to avoid predicting the contribution for network sizes of 
29 to 45 treatments based on a single network. Figure 3 shows that the contribution of longer paths wa
more important for networks that include many treatments. For example in a network of 10 treatments, 
direct evidence and indirect evidence with one intermediate comparator (paths of length 1 and 2) 
contributed 70% of the information to the estimation of the relative treatment effects. To achieve the same 
level of contribution in a network of 22 treatments, paths up to length 3 need to be considered. 
Table 2 summarizes the length of paths one has to consider to achieve a contribution of a certain 
level given the number of treatments included in the network. We considered four thresholds of 
cumulative contribution (70%, 80%, 90%, 95%). As an example, to achieve a contribution of 90% in a 
network with 20 treatments, we would have to consider paths of up to length 5. In contrast, for a network 
with eight treatments, paths of up to length 3 would be sufficient to achieve the same level of contribu ion. 
Figure 2, Figure 3 and Table 2 show the importance of the number of treatments involved in the network 
in the relative contribution of longer versus shorter paths. For instance, among networks of any size,on  
third of contribution comes from direct evidence and bout 80% from direct evidence and indirect paths 
with one intermediate comparator (Figure 2). However, less than 50% of contribution comes from direct 
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evidence and indirect paths with one intermediate comparator for networks with more than 16 treatments 
(Figure 3). 
(Table 2 here) 
The degrees of freedom from design by treatment interac ion models, graph radius, density and 
diameter also played a role in the relative contribu ion of longer versus shorter paths (Supplementary 
Material Figures 2-5). In networks with no closed loops (degrees of freedom equal to 0), direct evidence 
was more important compared to networks where loops existed. The relative importance of direct 
evidence decreased as loops, graph radius and diameter increased. Supplementary Material Figure 4 
suggests that dense networks have larger contributions from direct evidence. The greater contributions 
could be because density is, by definition, larger in networks with a small number of treatments. In small 
networks, where there are fewer indirect paths thanin large networks, we expect that the direct evidence 





In this study, we found that the contribution of direct and indirect paths of evidence to the 
estimation of NMA relative treatment effects depends on the size and the structure of the network. One of 
the main characteristics and advantages of NMA lies in the synthesis of direct and indirect evidence. The
extent to which each piece of evidence contributes to the summary results has, however, been unknown. 
To our knowledge, this is the first study empirically ssessing the relative contribution of paths of any
length to the estimation of NMA relative treatment ffects. Authors and reviewers interested in finding out 
from which sources of evidence the estimated NMA treatment effects originate can do so by using our 
freely available code (25,26); the two packages are the same in terms of functionality, but the Haskell 
package is superior in terms of speed. Alternatively, Figure 3 and Table 2 can give an approximation of 
the cumulative contribution of paths of lengths 1 to 6 according to the number of treatments in the 
network. 
Empirical studies have investigated whether this theoretical advantage is important in practice. 
Re-analyzing 44 networks of interventions, we showed that in 20% of comparisons, the evidence for the 
superiority  of one of the interventions was stronger with NMA than with pairwise meta-analysis (2). Lin 
et al. derived the distribution of the relative increase in precision in 40 NMAs. They concluded that e 
increase in precision of treatment estimates from NMA will depend on the availability of at least two 
studies contributing direct evidence and a network with well-connected treatments (3). Caldwell et al. 
examined the percentage increase in precision of a treatment comparison of interest in fictional networks 
of varying structure and amount of direct and indirect evidence (4). They found that, while including 
indirect evidence always increased precision, this increase was modest when direct evidence is strong and 
minimal when all indirect paths of one intermediate comparison are present. The empirical investigations 
provided insights into the conditions under which the gain in precision associated with NMA is 
substantial. While the relative increase by adding indirect evidence is well documented, it was unclear 
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until now what shorter, or longer paths contribute to the estimation of NMA effects, and whether this 
depends on the size and shape of the network. 
One important implication of this study’s results con erns the evaluation of the confidence in the 
relative treatment effects from NMA. Studies included in NMA may have a high risk of bias, e.g. due to 
inadequate blinding or concealment of allocation (27). The information on the paths that include such 
studies, and their contribution to each NMA treatment effect, is critical to judge the confidence that one 
can place in the results. Two systems have been proposed to evaluate the confidence in the results from
NMA (CINeMA (Confidence In Network Meta-Analysis) and GRADE (Grading of Recommendations 
Assessment, Development and Evaluation)) (7,8,28,29); the two systems follow similar considerations in 
some, but not all, of their recommendations. One important difference lies in the fact that CINeMA makes 
use of the contribution matrix described in (14) and used in the present study. In contrast, the GRADE 
system somewhat simplistically focuses on the most influential path of length 2, along with the direct 
evidence (28,29). The results of this empirical study emphasize that the GRADE approach is problematic 
as it discards a large amount of information, in particular in networks with many treatments. 
Our study has several limitations. We excluded networks that demonstrated evidence of 
inconsistency to make it less probable that NMA results, which inform decisions, are unreliable. However, 
we cannot exclude the possibility that inconsistency exists in some of the included networks because the 
power of tests of inconsistency is limited (30,31). Another limitation lies in the fact that there might be 
more than one way of selecting paths in each NMA treatment effect. We have elaborated on this issue in 
(14), where we showed that the consequence of this ambiguity does not substantially influence the results. 
We have not taken into account that the included NMAs may not be independent. Naudet et al. found that 
many NMAs “exhibit extensive overlap and potential redundancy” (32). It is not known how such 
dependencies between NMAs might have affected the relationship between the contributions of different 
paths and the size and structure of the network. Thus, readers should take into account that the same 
studies might have been included in different NMAs when interpreting our results. 
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This study is based on the collection of NMAs described in (15) and is to our knowledge the most 
extensive empirical study of NMAs conducted so far. This database was initially constructed (33) and 
subsequently updated (15) to be a useful resource to investigators planning simulations or empirical 
studies. The development of the R package nmadb that renders the re-use of the NMA outcome data 
possible constitutes a further step towards that aim (34). Apart from this study, several empirical projects 
have been undertaken (2,35–37) or planned (38) using th s NMA database. Empirical studies using 
different collections of NMAs have also been conducted (39–41). The networks included in these studies 
differed due to differences in inclusion criteria and the recency of the literature search. The substantial 
increase in NMA publications in recent years renders the update of the NMA database challenging. Its 
transformation into a regularly updated registry of NMAs might be the way forward.  
In conclusion, systematic reviewers need to consider wh ther strengthening the evidence with 
additional indirect evidence is worth the additional assumptions required. These considerations should 
take the broadness of the research question into account, and are informed by the findings of this empirical 
study. In summary, we showed that the amount by which longer paths contribute to the estimation of 
treatment effects from NMA is substantial, especially in networks with many treatments. The results of 
this empirical study reinforce the importance of using NMA in comparative effectiveness research and 
considering all paths of indirect evidence, including complex routes, when evaluating their results. 
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8 Figure legends 
Figure 1. Illustration of the method used to estimate the contribution of different paths, using the example of a 
published network meta-analysis [20] comparing four interventions for the treatment of achalasia of the 
oesophagus.  
The colours illustrate the three paths involved in the estimation of EBD vs OHM along with their percentage 
contributions. 
LHM: laparoscopic Heller myotomy, EBD: endoscopic balloon dilation, EBTI: endoscopic botulinum toxin 




Figure 2. Box plots of contributions of paths for all NMA treatment effects in the 213 network meta-analyses 




Figure 3. Cumulative contribution of paths of length 1 to 5 to NMA treatment effects in the 213 network meta-
analyses as a function of the number of treatments in the network.  
Dots indicate the average cumulative contribution per number of treatments; their size is proportional to the 
logarithm of inverse of standard errors. Curves are fitted using restricted cubic splines, weighted according to the 
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Table 1. Characteristics of 213 network meta-analyses included in the study.  
Values are frequencies (percentages) for categorical and median (IQR) for continuous characteristics. 
Characteristics of network meta-analyses Values 
General characteristics  
 Number of studies included 19 (11-33) 
 Number of treatments compared 6 (5-9) 
Network structure characteristics - 
 Shape of 
network 
None closed loop included (star network) 68 (32%) 
At least one closed loop included (non-star network) 145 (68%) 
 Degrees of freedom from the design by treatment interaction model 2 (0-6) 
 Graph density 0.42 (0.32-0.50) 
 Graph radius 1 (1-2) 
 Graph diameter 2 (2-3) 
Outcome characteristics - 
 
Measurement 
Binary  165 (77%) 




Odds Ratio 104 (49%) 
Risk Ratio 58 (27%) 
Risk Difference 3 (1.4%) 
Mean Difference 35 (16%) 
Standardized Mean Difference 13 (6.1%) 
 Direction  
of effect 
Beneficial 94 (44%) 
Harmful 119 (56%) 
 Objectivity Objective 78 (37%) 
Semi-objective 87 (41%) 
Subjective 48 (23%) 
 
 
Table 2. Cumulative contribution threshold per length of path to estimates of treatment effects in the 213 
network meta-analyses included in the study, according to the number of treatments in the network.  
Cells refer to number of treatments included in the network that correspond to achieving the cumulative 
contribution indicated in the column including paths up to the length indicated in the row. NA: non applicable. 
length threshold: 0.7 threshold: 0.8 threshold: 0.9 threshold: 0.95 
2 4-9 4-7 4 NA 
3 10-21 8-13 5-8 4-6 
4 22-29 14-29 9-19 7-13 
5 NA NA 20-29 14-23 
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What is new? 
Key findings 
• The contribution of different paths of direct and indirect evidence in network meta-analysis 
depends on the size and structure of networks 
What this adds to what is known 
• Considering long paths of evidence is very important in networks with many treatments 
What is the implication 
• Disregarding long paths of evidence is problematic when judging the confidence that one 
can place in network meta-analysis results 
• Authors and reviewers can use our freely available R package to examine contributions of 
different paths of evidence 
 
 
 
